Repare Therapeutics (RPTX) Competitors $1.20 +0.05 (+4.35%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.20 +0.01 (+0.42%) As of 04/17/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RPTX vs. MDWD, IVA, GNFT, RZLT, ACIU, HURA, DBVT, NBTX, DMAC, and CGCShould you be buying Repare Therapeutics stock or one of its competitors? The main competitors of Repare Therapeutics include MediWound (MDWD), Inventiva (IVA), Genfit (GNFT), Rezolute (RZLT), AC Immune (ACIU), TuHURA Biosciences (HURA), DBV Technologies (DBVT), Nanobiotix (NBTX), DiaMedica Therapeutics (DMAC), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Repare Therapeutics vs. MediWound Inventiva Genfit Rezolute AC Immune TuHURA Biosciences DBV Technologies Nanobiotix DiaMedica Therapeutics Canopy Growth Repare Therapeutics (NASDAQ:RPTX) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk. Is RPTX or MDWD more profitable? Repare Therapeutics has a net margin of -99.76% compared to MediWound's net margin of -142.29%. Repare Therapeutics' return on equity of -40.87% beat MediWound's return on equity.Company Net Margins Return on Equity Return on Assets Repare Therapeutics-99.76% -40.87% -35.07% MediWound -142.29%-82.17%-33.67% Which has higher valuation and earnings, RPTX or MDWD? MediWound has lower revenue, but higher earnings than Repare Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepare Therapeutics$53.48M0.95-$93.80M-$2.00-0.60MediWound$20.22M9.14-$6.72M-$3.07-5.57 Do insiders & institutionals have more ownership in RPTX or MDWD? 85.1% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 21.6% of Repare Therapeutics shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to RPTX or MDWD? In the previous week, Repare Therapeutics had 1 more articles in the media than MediWound. MarketBeat recorded 2 mentions for Repare Therapeutics and 1 mentions for MediWound. Repare Therapeutics' average media sentiment score of 0.50 beat MediWound's score of 0.22 indicating that Repare Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repare Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediWound 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer RPTX or MDWD? MediWound received 354 more outperform votes than Repare Therapeutics when rated by MarketBeat users. However, 64.18% of users gave Repare Therapeutics an outperform vote while only 62.23% of users gave MediWound an outperform vote. CompanyUnderperformOutperformRepare TherapeuticsOutperform Votes4364.18% Underperform Votes2435.82% MediWoundOutperform Votes39762.23% Underperform Votes24137.77% Do analysts rate RPTX or MDWD? Repare Therapeutics currently has a consensus target price of $4.50, indicating a potential upside of 275.00%. MediWound has a consensus target price of $31.33, indicating a potential upside of 83.24%. Given Repare Therapeutics' higher possible upside, analysts plainly believe Repare Therapeutics is more favorable than MediWound.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50MediWound 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, RPTX or MDWD? Repare Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. SummaryRepare Therapeutics beats MediWound on 12 of the 18 factors compared between the two stocks. Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RPTX vs. The Competition Export to ExcelMetricRepare TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.01M$6.44B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.31%P/E Ratio-0.606.8821.7317.77Price / Sales0.95231.02379.1697.65Price / CashN/A65.6738.2234.64Price / Book0.245.916.443.98Net Income-$93.80M$142.72M$3.21B$247.44M7 Day Performance33.33%4.33%2.82%1.82%1 Month Performance5.26%-12.80%-8.67%-6.98%1 Year Performance-60.26%-9.71%11.32%1.49% Repare Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RPTXRepare Therapeutics3.2828 of 5 stars$1.20+4.3%$4.50+275.0%-62.6%$51.01M$53.48M-0.60180Short Interest ↓High Trading VolumeMDWDMediWound1.198 of 5 stars$15.08+0.7%$31.33+107.8%-1.9%$162.76M$20.22M-5.2080Gap DownIVAInventiva1.6621 of 5 stars$3.10+1.0%$12.00+287.1%+4.3%$162.68M$9.20M0.00100Gap DownGNFTGenfit1.161 of 5 stars$3.25-3.4%$13.00+300.6%+0.7%$162.24M$76.06M0.00120Upcoming EarningsGap DownRZLTRezolute2.8959 of 5 stars$2.64+4.3%$24.38+823.3%-15.1%$159.81MN/A-2.1640Positive NewsGap UpACIUAC Immune2.5405 of 5 stars$1.59-4.2%$12.00+654.7%-38.8%$159.65M$27.31M-3.46140Analyst RevisionNews CoveragePositive NewsHURATuHURA BiosciencesN/A$3.64+7.7%$12.67+248.0%N/A$159.00MN/A0.00N/AAnalyst RevisionNews CoverageGap DownDBVTDBV Technologies2.6405 of 5 stars$7.44+14.5%$22.50+202.4%+17.4%$153.03M$15.73M-1.6580Earnings ReportAnalyst ForecastShort Interest ↑NBTXNanobiotix1.776 of 5 stars$3.17-3.1%$8.00+152.4%-37.9%$149.41M$36.22M0.00100DMACDiaMedica Therapeutics1.0961 of 5 stars$3.48-0.6%$8.00+129.9%+36.2%$149.14MN/A-6.2120Short Interest ↑Positive NewsGap UpCGCCanopy Growth2.144 of 5 stars$0.93+1.1%$2.00+114.9%-81.7%$147.59M$276.75M-0.243,150Options VolumeNews Coverage Related Companies and Tools Related Companies MediWound Alternatives Inventiva Alternatives Genfit Alternatives Rezolute Alternatives AC Immune Alternatives TuHURA Biosciences Alternatives DBV Technologies Alternatives Nanobiotix Alternatives DiaMedica Therapeutics Alternatives Canopy Growth Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RPTX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do to stop what's coming next for U.S. stocks. As you've seen your...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
